In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

With autoimmune pancreatitis linked to a higher cancer risk, doctors must use comprehensive imaging to avoid unnecessary ...

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung ...

Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551] Technology appraisal guidance Inclisiran for treating familial ...

Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301] Technology appraisal guidance Enfortumab vedotin with ...

Amgen acquired CD19-directed antibody Uplizna (inebilizumab) as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, and already has approval for the drug in AQP4 antibody-positive ...

In NMOSD, Soliris is also facing competition from Horizon Therapeutics' CD19-directed cytolytic antibody Uplizna (inebilizumab) and Roche's IL-6 inhibitor Enspryng (satralizumab). In the first ...

Dupilumab is now approved for CSU patients aged 12+ not controlled by H1 antihistamines, targeting IL-4 and IL-13 pathways. Phase 3 trials showed significant reductions in itch and urticaria ...